The most advanced is ISB 1342, a first-generation bispecific antibody targeting both cluster of differentiation 38 (CD38) on myeloma cells and CD3 on T cells, which is in phase 1 testing for ...

This T-cell engager simultaneously targets BCMA, CD38, and CD3, enhancing tumor-specific cytotoxicity while minimizing ...

a bispecific antibody that binds to CD3 and GPRC5D, a novel myeloma target. Both bispecifics have arisen out of J&J's longstanding alliance with Genmab, which also generated anti-CD38 blockbuster ...

Tecvayli (teclistamab) is an off-the-shelf bispecific antibody targeting both BCMA and CD3 which is also under ... an antibody directed at CD38 – and BCMA-targeted CAR-T therapy Carvykti ...

Johnson & Johnson is dropping a partnership with Genmab centered around a CD38 monoclonal antibody, prompting the latter company to discontinue development of the program. Back in 2019 ...

Despite initial clinical data showing efficacy, Genmab has decided to discontinue further clinical development of HexaBody-CD38. “While we are disappointed that J&J has decided not to advance ...

While the initial HexaBody-CD38 clinical data is promising and showed robust clinical efficacy, following a thorough evaluation of the data, the market landscape, and Genmab’s rigorous portfolio ...